Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: Results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial

Acta Neurologica Scandinavica

Volumn 114, Issue SUPPL. 185, 2006, Pages 3-7

  Sparks, D L ^a,d   Connor, D J ^a   Sabbagh, M N ^a   Petersen, R B ^c   Lopez, J ^a   Browne, P ^b  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b Sun Health Boswell Hospital   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Alzheimer's disease; Atorvastatin calcium; Clinical benefit; Pharmaco genetics; Treatment trial

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL; CHOLINESTERASE INHIBITOR; ESTROGEN; PLACEBO; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EXPOSURE; EVIDENCE BASED MEDICINE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TABLET; BLOOD; GENETICS; HOSPITALIZATION; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; CHOLESTEROL; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEUROPSYCHOLOGICAL TESTS; PYRROLES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33745739157     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00690.x     Document Type: Article

References (11)

1. NOTKOLA I-L, SULKAVA R, PEKKANEN J et al. Serum total cholesterol, apolipoprotein Eepsilon4 allele, and Alzheimer's disease. Neuroepidemiology 1998;17:14-20.
2. KIVIPELTO M, HELKALA E-L, HALLIKAINEN M et al. Elevated systolic blood pressure and high cholesterol levels at mid-live are risk factors for late-life dementia. Neurobiol Aging 2000;21:S174.
3. ROCKWOOD K, KIRKLAND S, HOGAN DB et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002;59:223-7.
4. JICK H, ZORNBERG GL, JICK SS, SESHADRI S, DRACHMAN DA. Statins and the risk of dementia. Lancet 2000;356:1627-31.
5. SPARKS DL, SABBAGH MN, CONNOR DJ et al. Atorvastatin for the treatment of mild-to-moderate Alzheimer's disease: preliminary results. Arch Neurol 2005;62:753-757.
6. MCKHANN G, DRACHMAN D, FOLSTEIN M. Clinical diagnosis of Alzheimer's disease. Neurology 1984;34:939-44.
7. MCKEITH IG, GALASKO D, KOSAKA K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
8. FOLSTEIN MF, FOLSTEIN SE, MCHUGH PR. 'Mini-Mental State': a practical method for grading the mental state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
9. ROSEN WG, MOHS RC, DAVIS KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:11-19.
10. WENHAM PR, PRICE WH, BLUNDELL G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158-9.
11. AISEN PS, SCHAFER KA, GRUNDMAN M et al. Effects of Rofecoxib or Naproxen vs placebo on Alzheimer disease progression. A randomized controlled trial. JAMA 2003;289:2819-26.